Harvard, Merck partner on AMD therapies

August 2006
Ophthalmology Times;8/15/2006, Vol. 31 Issue 16, p34
Trade Publication
The article reports on the license deal between Harvard Medical School and Merck & Co. Inc. to formulate potential therapies for macular degeneration in the United States. Harvard would provide Merck with licenses to specific molecules that may retard the production of lipofuscins, a risk factor of age-related macular degeneration and Stargardt's disease.


Related Articles

  • Biochemist strikes gold. Wadman, Meredith // Nature;6/8/2006, Vol. 441 Issue 7094, p689 

    The article reports an agreement between Harvard University and pharmaceutical company Merck & Co. Inc. that is designed to develop drugs to address a leading cause of blindness, namely, age-related macular degeneration. According to the deal, Merck will get exclusive licenses to a family of...

  • Alliospharma in license agreement with Merck. Pedersen, Amanda // Medical Device Daily;5/25/2010, Vol. 14 Issue 100, p4 

    This article reports on a commercial license agreement entered by Alliospharma with Merck to commercialize its first medical device.

  • Transgene inks licence deal.  // European Chemical News;2/10/2003, Vol. 78 Issue 2039, p21 

    Deals with the non-exclusive license agreement signed by bio-pharmaceutical company Transgene with Merck & Co. Details of the agreement; Information on both companies.

  • Vical, Merck Alter Licensing Agreement With Merck.  // San Diego Business Journal;9/1/2003, Vol. 24 Issue 35, p32 

    Focuses on the amendment of the licensing agreement by San Diego, California-based Vical Inc. with Merck & Co. Inc. for the use of its vaccine technology.

  • Merck, AstraZeneca in $50M licensing deal. Zanki, Tom // njbiz;9/16/2013, p2 

    The article reports that pharmaceutical company Merck & Co. Inc. has signed a $50 million licensing agreement with AstraZeneca PLC for its experimental cancer drug.

  • Merck, Luminex.  // Contract Pharma;Apr2013, Vol. 15 Issue 3, p117 

    The article focuses on the signed license and collaboration agreement of Merck and Luminex Corp. for the development of companion diagnostic to help screen the patients for the clinical development program of Merck.

  • Allergan and Molecular Partners Enter into Exclusive Alliance.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article reports that Allergan Inc. and Molecular Partners AG have entered into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of the treatment of exudative agerelated macular degeneration (AMD). The first is an...

  • Harvard Medical School, Merck In Cooperative Research Agreement.  // Bioscience Technology;Oct2007, Vol. 32 Issue 10, p14 

    The article reports on the cooperative research agreement between the Office of Technology Development (OTD) of Harvard Medical School (HMS) in Boston, Massachusetts and Merck. Under the terms of the agreement, research projects in oncology and central nervous system (CNS) disorders. Funds will...

  • Merck to use Epson Ink Technology to manufacture ink for large OLED displays.  // Paintindia;Nov2012, Vol. 62 Issue 11, p132 

    The article reports on the license agreement signed between Merck and Seiko Epson for inkjet inks used in the manufacture of organic light-emitting diode (OLED) displays.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics